SLC
OCUL icon

Second Line Capital’s Ocular Therapeutix OCUL Stock Holding History

Second Line Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27M Buy
638,640
+110,350
+21% +$1M 1.17% 17
2026
Q1 		$4.95M Buy
528,290
+27,544
+6% +$263K 0.94% 24
2025
Q4 		$6.08M Buy
500,746
+98,279
+24% +$1.19M 1.25% 18
2025
Q3 		$4.7M Buy
402,467
+17,000
+4% +$203K 0.97% 23
2025
Q2 		$3.58M Buy
385,467
+39,369
+11% +$308K 0.83% 27
2025
Q1 		$2.54M Buy
346,098
+6,000
+2% +$46.1K 0.65% 34
2024
Q4 		$2.9M Buy
340,098
+77,288
+29% +$754K 0.78% 32
2024
Q3 		$2.29M Hold
262,810
– – 0.62% 39
2024
Q2 		$1.8M Buy
+262,810
New +$1.62M 0.55% 40

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Second Line Capital's OCUL Position: Q2 2026 in Review

Second Line Capital increased its Ocular Therapeutix (OCUL) stake by 21% in Q2 2026, buying an estimated $1M and bringing the position to 638,640 shares worth $6.27M. The position accounts for 1.17% of the portfolio, ranked #17.

Second Line Capital first reported a position in OCUL in Q2 2024 and has held it in 9 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Second Line Capital held 638,640 shares of Ocular Therapeutix worth $6.27M as of Q2 2026.
  • Second Line Capital bought 110,350 Ocular Therapeutix shares in Q2 2026, an estimated $1M.
  • Ocular Therapeutix made up 1.17% of Second Line Capital's portfolio in Q2 2026, its #17 holding.
  • Second Line Capital first reported a position in Ocular Therapeutix in Q2 2024 and has held it in 9 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Second Line Capital's 13F filing for Q2 2026, filed 12 Aug 2026.